Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Respiratory diseases specialist Verona Pharma has announced the appointment of Richard Hennings to the company’s senior management team as commercial director. 31 March 2017
Takeda Pharmaceuticals says that Ricardo Marek has been appointed as the president of the Emerging Markets Business Unit (EM BU), based in Singapore, effective April 1, 2017 31 March 2017
Takeda Pharmaceutical said today that Giles Platford will assume the role of president of its Europe and Canada (EUCAN) business unit. In this role he will lead business operations in the region effective April 1, 2017. 30 March 2017
Daniel Gallagher – who from November 2011 to October 2015 was Commissioner of the US Securities and Exchange Commission (SEC) – has joined Netherlands-incorporated drugmaker Mylan as the company’s chief legal officer. 28 March 2017
Investors were clearly impressed by the appointment of Paul Bisaro as the chief executive of USA-based generics company Impax Laboratories as the firm’s share value shot up by 37% on Monday to $12.70. 28 March 2017
US biotech firm Alexion Pharmaceuticals has appointed Ludwig Hantson as chief executive and member of the board of directors, effective immediately. 27 March 2017
Claude Bertrand started on Monday in his new role as general director of research and development (R&D) and chief scientific officer (CSO) at privately-held French drugmaker Servier. 27 March 2017
US-based Boston Biomedical is making new senior appointments in oncology, as the company’s founder Chiang J. Li steps down from his role as chief executive. 23 March 2017
The US subsidiary of Japanese pharma major Eisai has appointed Kirk Shepard as senior vice president, global medical affairs of the Oncology Business Group. 17 March 2017
US pharma major Bristol-Myers Squibb has appointed Dr Thomas Lynch, Jr, as executive vice president and chief scientific officer, effective March 16, 2017. 9 March 2017
USA/Israel-based biotech firm BrainStorm Cell Therapeutics has appointed Ralph Kern to the positions of chief operating and chief medical officer, effective March 6, 2017. 6 March 2017
Denmark-based allergy specialist ALK-Abelló has appointed Hendrik Nolte as senior vice president of R&D for North America and International Markets, based in the USA. 3 March 2017
Investors in Ireland-incorporated Perrigo probably did not know where to turn on Monday and Tuesday amid news on the company’s management, job cuts, divestment of royalty payment rights on a multiple sclerosis drug and its publication of bleak financial guidance. 1 March 2017
Jakob Riis, executive vice president, head of North America Operations and president of Novo Nordisk Inc, has resigned, Danish diabetes care giant Novo Nordisk announced this morning. 1 March 2017
US biotech major Celgene Corp says that its president and chief operating officer (COO) Jacqualyn (Jackie) Fouse, has decided to retire from Celgene effective June 30, 2017. 24 February 2017
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Nathalie Moll as its new director general. 22 February 2017